|
| Human CD24 Protein-VLP (LTP10683) |
|
| LTP10683 |
|
| 100ug |
|
|
$1800 In stock |
| CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. |
| Recombinant Human CD24 Protein-VLP is expressed from Expi293. It contains Ser27-Gly59. |
|
| CD24 |
|
| Human |
|
| P25063-1 |
|
| Ser27-Gly59 |
|
| The target protein has a predicted MW of 5.0 kDa. |
|
| Immobilized Human CD24 VLP at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-CD24 Antibody, hFc Tag with the EC50 of 22.1ng/ml determined by ELISA. See testing image for detail. |
|
| 0 |
|
| Expi293 |
|
| > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
